Table 1.
Indirect comparison of oral anticoagulants for risk of acute coronary syndrome, stratified according to common control intervention
| Vitamin K antagonist as common control | Studies | Participants | Risk of ACS odds ratio (95% CI) |
|---|---|---|---|
| Apixaban vs. vitamin K antagonist | 1 | 18 201 | 0.88 (0.66, 1.17) |
| Rivaroxaban vs. vitamin K antagonist | 3 | 22 545 | 0.82 (0.64, 1.04) |
| Dabigatran vs. vitamin K antagonist | 4 | 26 076 | 1.54 (1.17, 2.02) |
| AIC via vitamin K antagonist | Apixaban vs. dabigatran | 0.57 (0.39, 0.85) | |
| Rivaroxaban vs. dabigatran | 0.53 (0.37, 0.77) | ||
| Placebo as common control | |||
| Apixaban vs. placebo | 3 | 11 124 | 0.90 (0.76, 1.07) |
| Rivaroxaban vs. placebo | 3 | 20 754 | 0.83 (0.71, 0.96) |
| Dabigatran vs. placebo | 2 | 32 41 | 1.87 (0.71, 4.91) |
| AIC via placebo | Apixaban vs. dabigatran | 0.48 (0.18, 1.29) | |
| Rivaroxaban vs. dabigatran | 0.44 (0.17, 1.18) | ||
| Enoxaparin as control | |||
| Apixaban vs. enoxaparin | 4 | 12 635 | 0.96 (0.38, 2.40) |
| Rivaroxaban vs. enoxaparin | 3 | 10 220 | 0.46 (0.16, 1.31) |
| Dabigatran vs. enoxaparin | 3 | 7649 | 0.89 (0.46, 1.72) |
| AIC via enoxaparin | Apixaban vs. dabigatran | 1.08 (0.35, 3.35) | |
| Rivaroxaban vs. dabigatran | 0.52 (0.15, 1.79) | ||